{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sinha J"],"funding":["Eunice Kennedy Shriver National Institute of Child Health and Human Development","NICHD NIH HHS"],"pagination":["329-344"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12746435"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["65(2)"],"pubmed_abstract":["<h4>Background</h4>Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking.<h4>Objective</h4>This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension.<h4>Methods</h4>Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mas"],"journal":["Clinical pharmacokinetics"],"pubmed_title":["Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity."],"pmcid":["PMC12746435"],"funding_grant_id":["R01 HD113201","HHSN275201000003C","R01 HD096435","R01HD096435","HHSN275201000003I","R01 HD102949"],"pubmed_authors":["West L","Clark K","Milleson C","Simone G","Craven S","Talbert J","John R","Mourani P","Dix M","Taylor L","Fearn L","Kennel P","Taylor J","James L","Riaz A","Pohl D","Hornik C","Tuttle A","Benoit M","Finkelstein Y","Eubanks S","Kowal K","Sims C","Farrar C","Nielsen C","Gerhardt B","Gonzalez D","Oldham M","Wrenn S","Rathore M","Mottes T","Taravath S","Kearns GL","Desmarasis D","Lacaze T","Klipner K","Hornik CD","Hastenson G","Howard L","Malone K","Lapid A","Howard E","Odero N","Al-Uzri A","Harper C","Grzesek K","Kernen K","Rutebemberwa A","Ralston K","Yogev R","Poff S","Autmizguine J","Massicotte C","Myer D","Ann DP","Shiloh-Malawsky Y","Greenberg R","Mahmoudi KTS","Konow C","Muller WJ","Swanson C","Kuchler A","Wiseheart M","Green T","Capparelli E","Bradley G","Kirby C","Zimmerman K","Balevic SJ","Paul I","Baisden N","O'Connor K","Goldstein S","Delmore P","Stubbs J","Van K","Sinha J","Stryjewski G","Muller W","Sierra Y","Lakhotia A","Michael A","Traisman B","Watt K","Kearns G","Sargent J","Murchison B","Laughon M","Patubo K","Comings J","Zemek R","Mariconti A","Beci R","Goldenberg N","Chen L","Anand R","Meyer M","Wade K","Sroka P","Deschenes J","Terrell T","Sund Z","Martinez M","Steinbeiss M","Litalien C","Chen JY","Jolly M","Bernhardt J","Opel K","Benjamin DK","Leradi S","DeGrauw T","Taylor-Zapata P","Paul IM","Blanks T","Filar L","Sullivan J","Arnold S","Arnold P","Alderman C","Simeon T","Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee","Harward M","Walker A","Drake A","DePaoli B","Joshi S","Hart M","Rumantir M","Perry J","Benjamin D","Burmester J","Cermak J","Joshi C","Payne E","Hansberry D","Borges A","Brown K","Anderson C","Dumitrascu M","McMilan H","Lague V","Lattimore S","DiDomenico D"],"additional_accession":[]},"is_claimable":false,"name":"Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity.","description":"<h4>Background</h4>Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking.<h4>Objective</h4>This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension.<h4>Methods</h4>Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mas","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T09:06:09.228Z","creation":"2026-07-02T03:08:33.287Z"},"accession":"S-EPMC12746435","cross_references":{"pubmed":["41247430"],"doi":["10.1007/s40262-025-01579-0"]}}